40
42
Growth Score
-11 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
259405
Abvance Therapeutics develops innovative solutions for diabetes care, including a novel coformulation of insulin and glucagon.
- David Maggs: CEO and Co-Founder
- Edward Raskin: Chief Executive OfficerPast Role: Beta Bionics, Co-Founder, Board Member, Public Benefit Officer
About the Company
Abvance Therapeutics is a biotechnology research company that focuses on innovative solutions to address unmet needs in diabetes care. The company is known for developing a novel coformulation of insulin and glucagon, which could revolutionize diabetes care. This treatment combines two well-understood and FDA-approved peptides to control glycemia
while mitigating the threat of hypoglycemia. The company's team of scientists and physicians have discovered this unique approach to diabetes treatment, aiming to reduce hypoglycemia and improve patient outcomes.
Women Founded
